Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid beta (Aβ) refers to peptides of 36–43 amino acids that are the principal component of amyloid plaques found in the brains of individuals with Alzheimer’s disease and other neurodegenerative conditions. These deposits are considered a hallmark pathological feature of Alzheimer’s disease, contributing to neuronal dysfunction and cognitive decline. Aβ exists in various aggregation states, from soluble monomers to neurotoxic oligomers and insoluble fibrils within plaques. Therapeutic strategies aim to reduce Aβ production, promote its clearance, or prevent its aggregation.
Inhibition of Aβ production; enhancement of Aβ clearance; prevention of Aβ aggregation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid beta deposits (Aβ).